Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH. de Vos van Steenwijk PJ, et al. Among authors: van der hulst jm, van der burg sh. Cancer Res. 2010 Apr 1;70(7):2707-17. doi: 10.1158/0008-5472.CAN-09-4299. Epub 2010 Mar 16. Cancer Res. 2010. PMID: 20233872
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R. van der Burg SH, et al. Among authors: van meijgaarden ke. Int J Cancer. 2001 Mar 1;91(5):612-8. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1119>3.0.co;2-c. Int J Cancer. 2001. PMID: 11267969
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.
de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH, Hickling JK. de Jong A, et al. Among authors: van der burg sh. Vaccine. 2002 Oct 4;20(29-30):3456-64. doi: 10.1016/s0264-410x(02)00350-x. Vaccine. 2002. PMID: 12297390 Clinical Trial.
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. Zwaveling S, et al. Among authors: van der burg sh. Cancer Res. 2002 Nov 1;62(21):6187-93. Cancer Res. 2002. PMID: 12414646
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH. Welters MJ, et al. Among authors: van den eeden sj, van der hulst jm, van der burg sh. Cancer Res. 2003 Feb 1;63(3):636-41. Cancer Res. 2003. PMID: 12566307
351 results